News
NXT-2 Vaccine Process Development and Formulation Underway
The National Institute of Allergy and Infectious Diseases of the US National Institute of Health has awarded a contract for process development and formulation of the NXT-2 Pan Fungal Vaccine to begin in 2023. This is a critical milestone in the development of the NXT-2 vaccine for invasive fungal infections.
The World Health Organization publishes the First Fungal Priority Pathogens list
In response to the rising global threat of fungal infections, the WHO published the First Fungal Priority Pathogen List (WHO FPPL). This is the first global effort to systematically prioritize fungal pathogens, considering their unmet research and development (R&D) needs and perceived public health importance.
Reference: https://www.who.int/publications/i/item/9789240060241
US Healthcare costs due to fungal infections top US $6B
https://scienmag.com/fungal-infections-cost-u-s-6-7b-in-a-year/
New research finds that fungal infections account for $6.7 billion in health care spending in the US 2018.
And that’s just the cases that were directly responsible for inpatient hospital stays.
Combined with secondary infections such as influenza and other clinical conditions, the total cost of hospital stays associated with fungal infections was in excess of $37.7 billion, comprising 1.1% of total U.S. national health care costs. This study used a pre-COVID hospitalization data set, and fungi-related costs are likely higher now, given the rise of secondary fungal infections in COVID-19 patients.